PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12763925-2 2003 The propensity of chemokines such as CC chemokine ligand 5 (CCL5)/RANTES (regulated on activation, normal T cell expressed and secreted) to bind to glycosaminoglycans and to form higher order oligomers has been shown to be essential for its in vivo activity. Glycosaminoglycans 148-166 C-C motif chemokine ligand 5 Homo sapiens 37-58 28333940-6 2017 At 20 WPV, the most significant transcriptional changes of Gag-specific CD8+ T cells were genes involved in TCR signaling, differentiation and maturation toward central memory cells, with increased expression of CCR7, TCRalpha, TCRbeta, CD28 and decreased expression of CTLA-4, IFN-gamma, RANTES, granzyme A and B. Glycosaminoglycans 59-62 C-C motif chemokine ligand 5 Homo sapiens 289-295 27091995-0 2016 Structural basis for oligomerization and glycosaminoglycan binding of CCL5 and CCL3. Glycosaminoglycans 41-58 C-C motif chemokine ligand 5 Homo sapiens 70-74 27091995-7 2016 However, this motif is partially buried when CCL3, CCL4, and CCL5 are oligomerized; thus, the mechanism by which GAG binds these chemokine oligomers has been elusive. Glycosaminoglycans 113-116 C-C motif chemokine ligand 5 Homo sapiens 61-65 27091995-8 2016 Our structures of GAG-bound CCL5 and CCL3 oligomers reveal that these chemokine oligomers have distinct GAG-binding mechanisms. Glycosaminoglycans 18-21 C-C motif chemokine ligand 5 Homo sapiens 28-32 27091995-8 2016 Our structures of GAG-bound CCL5 and CCL3 oligomers reveal that these chemokine oligomers have distinct GAG-binding mechanisms. Glycosaminoglycans 104-107 C-C motif chemokine ligand 5 Homo sapiens 28-32 19068144-4 2008 We therefore analyzed the impact of platelet derived glycosaminoglycans on the immobilization of the chemokine CCL5 (RANTES) on human microvascular endothelial cells and their influence on CCL5-CCR5 interactions. Glycosaminoglycans 53-71 C-C motif chemokine ligand 5 Homo sapiens 111-115 19068144-4 2008 We therefore analyzed the impact of platelet derived glycosaminoglycans on the immobilization of the chemokine CCL5 (RANTES) on human microvascular endothelial cells and their influence on CCL5-CCR5 interactions. Glycosaminoglycans 53-71 C-C motif chemokine ligand 5 Homo sapiens 117-123 18025279-0 2007 Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells. Glycosaminoglycans 0-18 C-C motif chemokine ligand 5 Homo sapiens 56-62 18025279-1 2007 The CC-chemokine regulated on activation, normal T-cell expressed, and presumably secreted (RANTES)/CCL5 mediates its biological activities through activation of G protein-coupled receptors, CCR1, CCR3, or CCR5, and binds to glycosaminoglycans. Glycosaminoglycans 225-243 C-C motif chemokine ligand 5 Homo sapiens 92-98 18025279-1 2007 The CC-chemokine regulated on activation, normal T-cell expressed, and presumably secreted (RANTES)/CCL5 mediates its biological activities through activation of G protein-coupled receptors, CCR1, CCR3, or CCR5, and binds to glycosaminoglycans. Glycosaminoglycans 225-243 C-C motif chemokine ligand 5 Homo sapiens 100-104 18025279-4 2007 RANTES/CCL5 binding to these cells depends on CCR1 and glycosaminoglycans. Glycosaminoglycans 55-73 C-C motif chemokine ligand 5 Homo sapiens 0-6 18025279-4 2007 RANTES/CCL5 binding to these cells depends on CCR1 and glycosaminoglycans. Glycosaminoglycans 55-73 C-C motif chemokine ligand 5 Homo sapiens 7-11 16807236-2 2006 CCL5 binding to glycosaminoglycans (GAGs) on the cell surface or in extracellular matrix sequesters CCL5, thereby immobilizing CCL5 to provide the directional signal. Glycosaminoglycans 16-34 C-C motif chemokine ligand 5 Homo sapiens 0-4 16807236-2 2006 CCL5 binding to glycosaminoglycans (GAGs) on the cell surface or in extracellular matrix sequesters CCL5, thereby immobilizing CCL5 to provide the directional signal. Glycosaminoglycans 16-34 C-C motif chemokine ligand 5 Homo sapiens 100-104 16807236-2 2006 CCL5 binding to glycosaminoglycans (GAGs) on the cell surface or in extracellular matrix sequesters CCL5, thereby immobilizing CCL5 to provide the directional signal. Glycosaminoglycans 16-34 C-C motif chemokine ligand 5 Homo sapiens 100-104 16807236-7 2006 We show that CCL5-CCR5-mediated apoptosis is dependent on cell surface GAG binding. Glycosaminoglycans 71-74 C-C motif chemokine ligand 5 Homo sapiens 13-17 16807236-9 2006 Moreover, the non-GAG binding variant, (44AANA47)-CCL5, fails to induce apoptosis. Glycosaminoglycans 18-21 C-C motif chemokine ligand 5 Homo sapiens 50-54 16807236-12 2006 Viewed altogether, these data suggest that CCL5-GAG binding and CCL5 aggregation are important for CCL5 activity in T cells, specifically in the context of CCR5-mediated apoptosis. Glycosaminoglycans 48-51 C-C motif chemokine ligand 5 Homo sapiens 43-47 15686348-2 2005 PEG was attached to a 67-amino acid fully synthetic CCL-5 (RANTES) analogue at its GAG binding site both to reduce aggregation and to increase the circulating lifetime. Glycosaminoglycans 83-86 C-C motif chemokine ligand 5 Homo sapiens 52-57 15686348-2 2005 PEG was attached to a 67-amino acid fully synthetic CCL-5 (RANTES) analogue at its GAG binding site both to reduce aggregation and to increase the circulating lifetime. Glycosaminoglycans 83-86 C-C motif chemokine ligand 5 Homo sapiens 59-65 18025279-7 2007 The fact that RANTES/CCL5-induced migration and invasion of Huh7 cells are both strongly inhibited by anti-CCR1 antibodies and heparin, as well as by beta-d-xyloside treatment of the cells, suggests that CCR1 and glycosaminoglycans are involved in these events. Glycosaminoglycans 213-231 C-C motif chemokine ligand 5 Homo sapiens 14-20 18025279-7 2007 The fact that RANTES/CCL5-induced migration and invasion of Huh7 cells are both strongly inhibited by anti-CCR1 antibodies and heparin, as well as by beta-d-xyloside treatment of the cells, suggests that CCR1 and glycosaminoglycans are involved in these events. Glycosaminoglycans 213-231 C-C motif chemokine ligand 5 Homo sapiens 21-25 18025279-8 2007 We then show by surface plasmon resonance that synthetic glycosaminoglycan mimetics, OTR4120 or OTR4131, directly bind to RANTES/CCL5. Glycosaminoglycans 57-74 C-C motif chemokine ligand 5 Homo sapiens 122-128 18025279-8 2007 We then show by surface plasmon resonance that synthetic glycosaminoglycan mimetics, OTR4120 or OTR4131, directly bind to RANTES/CCL5. Glycosaminoglycans 57-74 C-C motif chemokine ligand 5 Homo sapiens 129-133 18025279-10 2007 Therefore, targeting the RANTES-glycosaminoglycan interaction could be a new therapeutic approach for human hepatocellular carcinoma. Glycosaminoglycans 32-49 C-C motif chemokine ligand 5 Homo sapiens 25-31 15355933-10 2005 Finally, RANTES forms GAG-dependent complexes with the shed ectodomains of SD-1 and SD-4 as well as with those of CD44. Glycosaminoglycans 22-25 C-C motif chemokine ligand 5 Homo sapiens 9-15 14637022-6 2003 This suggests that glycosaminoglycans (GAGs) are involved in RANTES binding to the PGs and that such bindings facilitate the subsequent interaction of RANTES with CCR5, on the MDM, characterized by low membrane expression of CCR5. Glycosaminoglycans 19-37 C-C motif chemokine ligand 5 Homo sapiens 61-67 12773479-5 2003 Glycosaminoglycans removal from the cells by glycosaminidases treatment prevented RANTES binding to SD-1 and -4 and decreased RANTES binding to CCR5 on the CCR5-positive HeLa cells. Glycosaminoglycans 0-18 C-C motif chemokine ligand 5 Homo sapiens 82-88 12773479-5 2003 Glycosaminoglycans removal from the cells by glycosaminidases treatment prevented RANTES binding to SD-1 and -4 and decreased RANTES binding to CCR5 on the CCR5-positive HeLa cells. Glycosaminoglycans 0-18 C-C motif chemokine ligand 5 Homo sapiens 126-132 12773479-6 2003 Removal of glycosaminoglycans by glycosaminidases treatment of the complexes, RANTES/SD-1/SD-4/+/-CCR5, immobilized on beads, reversed SD-1 and -4 bindings. Glycosaminoglycans 11-29 C-C motif chemokine ligand 5 Homo sapiens 78-84 12763925-2 2003 The propensity of chemokines such as CC chemokine ligand 5 (CCL5)/RANTES (regulated on activation, normal T cell expressed and secreted) to bind to glycosaminoglycans and to form higher order oligomers has been shown to be essential for its in vivo activity. Glycosaminoglycans 148-166 C-C motif chemokine ligand 5 Homo sapiens 60-64 12763925-2 2003 The propensity of chemokines such as CC chemokine ligand 5 (CCL5)/RANTES (regulated on activation, normal T cell expressed and secreted) to bind to glycosaminoglycans and to form higher order oligomers has been shown to be essential for its in vivo activity. Glycosaminoglycans 148-166 C-C motif chemokine ligand 5 Homo sapiens 66-72 12847218-3 2003 In particular, mac25/AGM interacted with not only the extracellular matrix proteins and glycosaminoglycans that are expressed in most blood vessels including HEVs, but also with some chemokines that are implicated in the regulation of lymphocyte trafficking, such as the secondary lymphoid-tissue chemokine (SLC; CCL21), IFN-gamma-inducible protein 10 (IP-10; CXCL10), and RANTES (CCL5). Glycosaminoglycans 88-106 C-C motif chemokine ligand 5 Homo sapiens 373-379 12847218-3 2003 In particular, mac25/AGM interacted with not only the extracellular matrix proteins and glycosaminoglycans that are expressed in most blood vessels including HEVs, but also with some chemokines that are implicated in the regulation of lymphocyte trafficking, such as the secondary lymphoid-tissue chemokine (SLC; CCL21), IFN-gamma-inducible protein 10 (IP-10; CXCL10), and RANTES (CCL5). Glycosaminoglycans 88-106 C-C motif chemokine ligand 5 Homo sapiens 381-385 10917892-6 2000 Specific inhibitors of RANTES-induced activation, such as soluble glycosaminoglycans, MIP-1alpha and MIP-1beta, acted by preventing the binding of RANTES on the cell surface. Glycosaminoglycans 66-84 C-C motif chemokine ligand 5 Homo sapiens 23-29 11836402-0 2002 Interaction of the CC-chemokine RANTES with glycosaminoglycans activates a p44/p42 mitogen-activated protein kinase-dependent signaling pathway and enhances human immunodeficiency virus type 1 infectivity. Glycosaminoglycans 44-62 C-C motif chemokine ligand 5 Homo sapiens 32-38 11836402-7 2002 Here we show that activation of both PTK and MAPK is involved in the enhancement of HIV-1 infectivity caused by RANTES in cells that lack GPCRs for RANTES but which express GAGs. Glycosaminoglycans 173-177 C-C motif chemokine ligand 5 Homo sapiens 112-118 10917892-6 2000 Specific inhibitors of RANTES-induced activation, such as soluble glycosaminoglycans, MIP-1alpha and MIP-1beta, acted by preventing the binding of RANTES on the cell surface. Glycosaminoglycans 66-84 C-C motif chemokine ligand 5 Homo sapiens 147-153 10766793-0 2000 Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. Glycosaminoglycans 105-123 C-C motif chemokine ligand 5 Homo sapiens 31-37 10504268-3 1999 Chemokines bind to glycosaminoglycans on human umbilical vein endothelial cells (HUVECs) with affinities in the micromolar range: RANTES > MCP-1 > IL-8 > MIP-1alpha. Glycosaminoglycans 19-37 C-C motif chemokine ligand 5 Homo sapiens 130-136 10588734-5 1999 To further investigate this dependence, we examined whether soluble GAG could reconstitute the biological activities of RANTES on glycanase-treated cells. Glycosaminoglycans 68-71 C-C motif chemokine ligand 5 Homo sapiens 120-126 10504268-5 1999 RANTES binding showed the widest discrimination between glycosaminoglycans (700-fold), whereas MIP-1alpha was the least selective. Glycosaminoglycans 56-74 C-C motif chemokine ligand 5 Homo sapiens 0-6 9815269-0 1998 A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. Glycosaminoglycans 63-80 C-C motif chemokine ligand 5 Homo sapiens 105-111 9815269-0 1998 A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling. Glycosaminoglycans 82-85 C-C motif chemokine ligand 5 Homo sapiens 105-111 9815269-8 1998 Taken together, these studies demonstrate that the COOH-terminal alpha-helical region of RANTES plays a key role in GAG-binding, antiviral activity, and intracellular Ca2+ signaling and support a model in which GAGs play a key role in the biological activities of this chemokine. Glycosaminoglycans 116-119 C-C motif chemokine ligand 5 Homo sapiens 89-95 9891023-11 1999 The artificial proteoglycans were also used as a model system to explore the glycosaminoglycan binding properties of basic-fibroblast growth factor and the chemokine RANTES. Glycosaminoglycans 77-94 C-C motif chemokine ligand 5 Homo sapiens 166-172 9354625-9 1997 The endothelial cell binding sites for IL-8, RANTES, and MCP-1 were deduced to be glycosaminoglycans since competition assays showed the biphasic curves and micromolar IC50 values seen in studies with immobilized heparin, and mRNA for known chemokine receptors was not detected. Glycosaminoglycans 82-100 C-C motif chemokine ligand 5 Homo sapiens 45-51 9354625-12 1997 Removal of glycosaminoglycans from CHO cells expressing chemokine receptors CXCR1, CCR1, or CCR2 resulted in 40-70% decreases in the binding of RANTES, MCP-1, IL-8, and MIP-1alpha. Glycosaminoglycans 11-29 C-C motif chemokine ligand 5 Homo sapiens 144-150